Announced on its homepage: “Avammune Therapeutics (a spin-off from Aten Porus Lifesciences) secures a round of financing for completion of IND enabling studies for t…”.
Observed on the company’s website; business claims are not independently verified.
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
February 2026 – November 2026 · 2 captures · latest observed messagingMulti-Modal Cancer Therapies
Avammune develops first-in-class and best-in-class small-molecule therapeutics across foundational therapeutic modalities in oncology, enabling early POC-driven partnerships for the development of pio